This protocol is judged by an institutional critique board, an independent group that assessments any clinical trials involving individuals. If a review includes a Schedule I drug, after the board approves the protocol as moral, the researchers really need to apply for an investigational new drug (IND) variety with the FDA.When underneath the impac